The FDA awarded two national priority review vouchers through its Commissioner’s National Priority Voucher pilot program on Dec. 19, bringing the total granted to 18.
The latest vouchers were issued for enlicitide decanoate, an oral PCSK9 inhibitor aimed at lowering LDL cholesterol, and sacituzumab tirumotecan, a trophoblast cell-surface antigen 2-directed antibody-drug conjugate. The program, launched in June, is designed to accelerate the review of therapies that address public health priorities or improve drug affordability and access.
Previous recipients include treatments for sickle cell disease, obesity, Type 1 diabetes, rectal cancer and drug-resistant tuberculosis. The FDA issued its first review decision under the program Dec. 9.
Voucher holders receive enhanced support throughout the review process, with applications targeted for decisions within one to two months.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.